iSBTc 22nd Annual Meeting

November 2 - 4, 2007
Seaport World Trade Center
Boston, Massachusetts

Presentations
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the Click to view presentation next to the speaker's name for the slides you wish to view.

Schedule at a Glance  |  Presentations  |  Friday Presentations  |  Saturday Presentations  |  Sunday Presentations

Friday, November 2
7:50 am - 8:00 am President's Welcome
Jon M. Wigginton, MD - Merck & Co., Inc.
8:00 am - 8:45 am Richard V. Smalley Memorial Lectureship
Interferons (IFNs) for Cancer: Defining Biological Response Modification and
Full Therapeutic Potential
Click to view presentationErnest C. Borden, MD - Cleveland Clinic Foundation
8:45 am - 11:30 am Plenary Session: Cellular Therapies
Co-Chairs:
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
James C. Yang, MD - National Cancer Institute
8:45 am - 9:15 am Adoptive Cellular Therapy: Sustained Regression of Large Tumor Burdens with In Vitro Expanded T-Cells
Click to view presentationJames C. Yang, MD - National Cancer Institute
9:15 am - 9:45 am Targeting Tumors with Genetically Enhanced T Lymphocytes
Click to view presentationMichel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
9:45 am - 10:15 am Engineering Cytolytic Effector Cells for Glioma Immunotherapy
Using Gene Insertion and Zinc Finger Nuclease Genomic Editing

Click to view presentationMichael C.V. Jensen, MD - City of Hope / Beckman Research Institute
10:45 am - 11:00 am A Comprehensive Platform for T Cell Expansion Based on Biodegradable Artificial Antigen-Presenting Microparticulates
Tarek Fahmy, PhD - Yale University
11:00 am - 11:15 am Tumor-Specific CD4 T Cells are Required for Long-Term Anti-Tumor Immunity in Reconstituted Lymphopenic Animals
Kevin Friedman, PhD - Earle A. Chiles Research Institute
11:15 am - 11:30 am T-Cell Therapy for the Control of EBV-Related Nasopharyngeal Carcinoma
Click to view presentationPaulo Pedrazzoli, MD - Ospedale Niguarda Ca’ Granda
1:30 pm - 3:30 pm Plenary Session: Characterizing the Host Response to Cancer
Co-Chairs:
George Coukos, MD, PhD - University of Pennsylvania Medical Center
Thomas F. Gajewski, MD, PhD - University of Chicago
1:30 pm - 2:00 pm Stat3 Mediates a Crosstalk Between Tumor Cells and Immune Cells in the Tumor Microenvironment
Click to view presentationHua Yu, PhD - City of Hope National Medical Center
2:00 pm - 2:15 pm Antibody Immunity to a Panel of Oncogenic Proteins May Predict Presence of Colon Cancer and Stage of Disease
Click to view presentationVivian Goodell, MPH - University of Washington
2:15 pm - 2:30 pm A Possible Role for Regulatory T-Cells in Survival Differences Between Helicobacter Pylori Posititve and Negative Gastric Cancer Patients After Curative Tumor Resection
Click to view presentationHauke Winter, MD - Klinikum Grosshadern, Ludwig-Maximilians University of Munich
2:30 pm - 2:45 pm Immunophenotypic Analysis of Melanoma Metastases: A New Approach for Prognostication in Stage IV Melanoma
Click to view presentationAlicia M. Terando, MD - John Wayne Cancer Institute
2:45 pm - 3:00 pm A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on
CD8+ T Effector/Memory Cells Via CD137

Click to view presentationRimas J. Orentas, PhD - Medical College of Wisconsin
3:00 pm - 3:30 pm Endothelin (B) Receptor Mediates the Endothelial Barrier to T-Cell Homing to Tumors, and Its Neutralization Enables Tumor Immune Therapy
George Coukos, MD, PhD - University of Pennsylvania Medical Center
3:45 pm - 5:15 pm Concurrent Session I: Cytokines
Co-Chairs:
Michael T. Lotze, MD - University of Pittsburgh
Crystal Mackall, MD - National Cancer Institute
3:45 pm - 4:15 pm Interleukin 1 Family Members Regulate Tumor Immunity in Response
to Damage Associated Molecular Pattern Molecules (DAMPs)

Click to view presentationMichael T. Lotze, MD - University of Pittsburgh Cancer Institute
4:15 pm - 4:30 pm IL-24 and Its Role in Wound Healing
Click to view presentationNancy J. Poindexter, PhD - MD Anderson Cancer Center
4:30 pm - 4:45 pm Intra-Tumoral IL-12 Promotes CD8 + T-Effector/Memory Cell-
Mediated IFN-Gamma and FASL-Dependent Elimination of CD4+ CD25+
FOX3+ T-Suppressor Cells from Tumors

Click to view presentationMehmet O. Kilinc, PhD - University at Buffalo / SUNY
4:45 pm - 5:15 pm Interleukin-7 Therapy in Humans: Proof-of-Principle
Crystal Mackall, MD - National Cancer Institute, Pediatric Oncology
3:45 pm - 5:15 pm Concurrent Session II: Angiogenesis and Vascular Therapies
Co-Chairs:
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
Renata Pasqualini, PhD - MD Anderson Cancer Center
3:45 pm - 3:50 pm Introduction
Renata Pasqualini, PhD - MD Anderson Cancer Center
3:50 pm - 4:25 pm Ligand-Directed Targeting and Molecular Genetic Imaging in
Diseases with an Angiogenesis Component

Wadih Arap, MD, PhD - MD Anderson Cancer Center
4:25 pm - 5:00 pm Tie2-Expressing Monocytes: a Novel Lineage of Proangiogenic Cells
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
5:00 pm - 5:15 pm Impaired Angiogenesis in Aminopeptidase N-Null Mice
Click to view presentationRoberto Rangel, PhD - MD Anderson Cancer Center
Saturday, November 3
8:00 am - 8:45 am Saturday Keynote Address
Adoptive T Cell Therapy: Grand Challenges and Opportunities
Click to view presentationCarl H. June, MD - University of Pennsylvania
8:45 am - 11:30 am Plenary Session: Immuoregulation and Mediated Tolerance
Co-Chairs:
Vincenzo Bronte, MD - Istituto Oncologico Veneto
F. Stephen Hodi, MD - Dana-Farber Cancer Institute
8:45 am - 9:00 am Elevated Foxp3+CD4+CD25+ Regulatory T Cells in Tumor-Bearing Mice Suppress T-Cell Priming, Effector-Cell Function and Anti-Tumor Immunity
Zuqiang Liu, PhD - University of Pittsburgh School of Medicine
9:00 am - 9:30 am Manipulating Immune Tolerance Unmasks the Latent Immune-Modulating Potential of Cancer Therapeutics
Leisha A. Emens, MD, PhD - Johns Hopkins University
9:30 am - 9:45 am Different Flavors of Regulatory T-Cell (Treg) Subsets in
Patients with Cancer and Their Role in Tumor Escape

Click to view presentationChristoph Bergmann, MD, PhD - University of Duisburg-Essen
9:45 am - 10:00 am Ex Vivo Depletion of CD81+ Tumor-Induced Regulatory T Cells Restores Priming of Tumor-Specific Effector T Cells Generated in Reconstituted, Lymphopenic Hosts
Christian Poehlein, MD - Earle A. Chiles Research Institute
10:00 am - 10:15 am Foxp3 is Expressed by Tumor Cells, Virally Transformed B Cells, and Germ Cells
Click to view presentationWeisan Chen, PhD - Ludwig Institute for Cancer Research
10:45 am - 11:00 am TGF-Beta Signaling Plays a Crucial Role for De Novo Induction of
Adaptive Regulatory T Cells but Is Not Required for the
Immunosuppressive Effect Mediated by Tumor-Induced Regulatory T Cells

Ulf Petrausch, MD - Earle A. Chiles Research Institute
11:00 am - 11:30 am Myeloid-Derived Suppressor Cells in Cancer
Vincenzo Bronte, MD - Istituto Oncologico Veneto
1:30 pm - 3:00 pm Concurrent Session I: Tumor Recognition / Immune Evasion
Co-Chairs:
Paul F. Robbins, PhD - National Cancer Institute
Thomas Spies, PhD - Fred Hutchinson Cancer Research Center
1:30 pm - 2:00 pm Adoptive Immunotherapy of Malignancies with Gene Modified, EBV-Specific, Cytotoxic T-Cell Lines
Click to view presentationMalcolm K. Brenner, MD, PhD - Baylor College of Medicine
2:00 pm - 2:30 pm Therapeutically Accessible Molecules That Regulate the Regulators
Click to view presentationDrew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine
2:30 pm - 2:45 pm Tumor-Derived Macrophage Migration Inhibitory Factor (MIF)
Inhibits Immune Reactivity to Neuroblastoma In Vivo

Click to view presentationBryon D. Johnson, PhD - Medical College of Wisconsin
2:45 pm - 3:00 pm 5-aza-2’- Deoxycytidine Treatment Increases Expression of Tumor
Associated Antigens in Human Melanoma

Click to view presentationTimothy Haggerty, PhD - CytoCure LLC
1:30 pm - 3:00 pm Concurrent Session II: New Agents
Co-Chairs:
Elizabeth A. Repasky, PhD - Rosewell Park Cancer Institute
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
1:30 pm - 1:45 pm PTTG-1: An Immunological Target for Multiple Myeloma
Maurizio Chiriva, PhD - Texas Tech University Health Sciences Center
1:45 pm - 2:00 pm A Phase II Study of Tremelimumab (CP-675,206), an Anti-CTLA4
Monoclonal Antibody, in Patients with Refractory Metastatic Colorectoal Cancer

Click to view presentationKi Y. Chung, MD - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:15 pm Immune-Related Adverse Events in Patients with Melanoma Treated with Tremelimumab (CP-675,206)
Dimitri Pavlov, PhD - Pfizer, Inc.
2:15 pm - 2:30 pm EGFRVIII Vaccine (CDX-110) Alone and with Simultaneous
Temozolomide in Patients with Newly Diagnosed, Resected, EGFRVIII Positive GBM

Click to view presentationJohn Sampson, MD, PhD - Duke University Medical Center
2:30 pm - 3:00 pm Novel Agents in Renal Cell Carcinoma: Challenges and
Opportunities in Capitalizing on Active Therapy

Click to view presentationBrian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
3:20 pm - 4:45 pm iSBTc Presidential Session
Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
3:20 pm - 3:25 pm Introduction
Jon M. Wigginton, MD - Merck & Co., Inc.
3:25 pm - 3:45 pm Apoptosis of Circulating Tumor-Antigen Specific TH1 CD4+ T Cells from Melanoma Patients
Amy K. Wesa, PhD - University of Pittsburgh School of Medicine
3:45 pm - 4:05 pm Priming and Selection of Allorestricted, Peptide-Specific T Cells for Adoptive Therapy of Tumors
Susanne Wilde - Institute of Molecular Immunology
4:05 pm - 4:25 pm Retrospective Analysis of Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma Who had Received Prior Antiangiogenic Therapy
Click to view presentationTalya Schwarzberg, MD - Beth Israel Deaconess Medical Center
4:25 pm - 4:45 pm CD4+CD25highFoxp3+ T Regulatory Cells Kill Autologous CD8(+) and
CD4(+) T Cells Using GranzymeB and Fas/FasL-Mediated Pathways

Click to view presentationLaura Strauss, PhD - San Raffaele Telethon Institute for Gene Therapy
Sunday, November 4
8:00 am - 8:30 am Update: 2006 Mini-Symposium Update
Chair:
George Coukos, MD, PhD - University of Pennsylvania Medical Center

Speaker:
Click to view presentationMichael B. Atkins, MD - Beth Israel Deaconess Medical Center
8:30 am - 8:45 am Update: National Cancer Institute Immunotherapy Agent Workshop
Click to view presentationMartin A. Cheever, MD - Fred Hutchinson Cancer Research Center
8:45 am - 11:00 am Plenary Session: Vaccines / Dendritic Cells
Co-Chair:
Mary L. Disis, MD - University of Washington
Lothar H. Finke, MD - ARGOS Therapeutics
8:45 am - 9:15 am The Development of Provenge® (Sipuleucel-T) an Active Cellular
Immunotherapy for Prostate Cancer

Click to view presentationDavid L. Urdal, PhD - Dendreon Corporation
9:15 am - 9:30 am Long-Term Survival in Patients with Metastatic Melanoma Vaccinated
with Melanoma-Antigen Loaded Dendritic Cells

Click to view presentationJoseph W. Fay, MD - Baylor University Medical Center
9:30 am - 9:45 am Phase II Trial of a 10-Epitope CTL Vaccine, IDM-2101, in
Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy

Minal Barve, MD - Mary Crowley Cancer Research Centers
9:45 am - 10:00 am Different DC Populations Interact with Memory & Effector T Cells, or with Treg Cells
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
10:00 am - 10:15 am Features of Lympoid Neogenesis After Dermal Injection of Incomplete Freund’s Adjuvant with or without Peptides
Craig L. Slingluff, Jr., MD - University of Virginia
10:15 am - 10:30 am IMA901, a Novel Multi-Peptide Vaccine for the Treatment of Renal
Cell Carcinoma - Pre-Clinical and Clinical Studies and Implications for Combination with Other Agents

Click to view presentationHarpreet Singh, PhD - Immatics Biotechnologies GmbH
10:30 am - 11:00 am Insulin like Growth Factor Receptor Family Members: Essential Tumor Antigens in Breast Cancer
Click to view presentationMary L. Disis, MD - University of Washington
11:00 am - 11:15 am Refreshment Break
11:15 am - 12:45 pm Hot Topic Sessions: Vaccines / Dendritic Cells
Moderators:
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
Jon M. Wigginton, MD - Merck & Co., Inc.

Participants:
Click to view presentationBrent A. Blumenstein, PhD - TriArc Consulting
Click to view presentationLee S. Simon, MD - Beth Israel Deaconess Medical Center
Click to view presentationCharles Drake, MD, PhD - Johns Hopkins University
Click to view presentationDavid L. Urdal, PhD - Dendreon Corporation
James W. Young, MD - Memorial Sloan-Kettering Cancer Center
12:45 pm Meeting Adjourns

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.